FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2195280273> ?p ?o ?g. }

• W2195280273 endingPage "44133" @default.
• W2195280273 startingPage "44123" @default.
• W2195280273 abstract "// Johan Van den Bergh 1 , Yannick Willemen 1 , Eva Lion 1 , Heleen Van Acker 1 , Hans De Reu 1 , Sébastien Anguille 1 , Herman Goossens 2 , Zwi Berneman 1 , Viggo Van Tendeloo 1,* and Evelien Smits 1,3,* 1 Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium 2 Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium 3 Center for Oncological Research Antwerp, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium * shared senior authors Correspondence to: Johan Van den Bergh, email: // Keywords : interleukin-15 transpresentation, IL-15 receptor α, dendritic cells, mRNA elektroporation, natural killer cells, Immunology and Microbiology Section, Immune response, Immunity Received : September 15, 2015 Accepted : November 28, 2015 Published : December 09, 2015 Abstract In cancer immunotherapy, the use of dendritic cell (DC)-based vaccination strategies can improve overall survival, but until now durable clinical responses remain scarce. To date, DC vaccines are designed primarily to induce effective T-cell responses, ignoring the antitumor activity potential of natural killer (NK) cells. Aiming to further improve current DC vaccination outcome, we engineered monocyte-derived DC to produce interleukin (IL)-15 and/or IL-15 receptor alpha (IL-15Rα) using mRNA electroporation. The addition of IL-15Rα to the protocol, enabling IL-15 transpresentation to neighboring NK cells, resulted in significantly better NK-cell activation compared to IL-15 alone. Next to upregulation of NK-cell membrane activation markers, IL-15 transpresentation resulted in increased NK-cell secretion of IFN-γ, granzyme B and perforin. Moreover, IL-15-transpresenting DC/NK cell cocultures from both healthy donors and acute myeloid leukemia (AML) patients in remission showed markedly enhanced cytotoxic activity against NK cell sensitive and resistant tumor cells. Blocking IL-15 transpresentation abrogated NK cell-mediated cytotoxicity against tumor cells, pointing to a pivotal role of IL-15 transpresentation by IL-15Rα to exert its NK cell-activating effects. In conclusion, we report an attractive approach to improve antitumoral NK-cell activity in DC-based vaccine strategies through the use of IL-15/IL-15Rα mRNA-engineered designer DC." @default.
• W2195280273 created "2016-06-24" @default.
• W2195280273 creator A5010374583 @default.
• W2195280273 creator A5020647206 @default.
• W2195280273 creator A5023991993 @default.
• W2195280273 creator A5030421066 @default.
• W2195280273 creator A5035783382 @default.
• W2195280273 creator A5037454723 @default.
• W2195280273 creator A5041713803 @default.
• W2195280273 creator A5069411021 @default.
• W2195280273 creator A5069580321 @default.
• W2195280273 creator A5086410678 @default.
• W2195280273 date "2015-12-09" @default.
• W2195280273 modified "2023-10-16" @default.
• W2195280273 title "Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity" @default.
• W2195280273 cites W113686829 @default.
• W2195280273 cites W1556664229 @default.
• W2195280273 cites W1608238667 @default.
• W2195280273 cites W1758585762 @default.
• W2195280273 cites W1930470734 @default.
• W2195280273 cites W1963991141 @default.
• W2195280273 cites W1967877143 @default.
• W2195280273 cites W1968321644 @default.
• W2195280273 cites W1976102853 @default.
• W2195280273 cites W1984285761 @default.
• W2195280273 cites W1988881559 @default.
• W2195280273 cites W1994074703 @default.
• W2195280273 cites W1998887003 @default.
• W2195280273 cites W2000715091 @default.
• W2195280273 cites W2004037261 @default.
• W2195280273 cites W2008232752 @default.
• W2195280273 cites W2019530616 @default.
• W2195280273 cites W2023172306 @default.
• W2195280273 cites W2029578639 @default.
• W2195280273 cites W2029586649 @default.
• W2195280273 cites W2031929209 @default.
• W2195280273 cites W2031976232 @default.
• W2195280273 cites W2037003210 @default.
• W2195280273 cites W2039422212 @default.
• W2195280273 cites W2047598314 @default.
• W2195280273 cites W2049195346 @default.
• W2195280273 cites W2057599316 @default.
• W2195280273 cites W2059542392 @default.
• W2195280273 cites W2060928633 @default.
• W2195280273 cites W2063785094 @default.
• W2195280273 cites W2069486064 @default.
• W2195280273 cites W2077032836 @default.
• W2195280273 cites W2081710396 @default.
• W2195280273 cites W2087665046 @default.
• W2195280273 cites W2100070386 @default.
• W2195280273 cites W2101627412 @default.
• W2195280273 cites W2119312822 @default.
• W2195280273 cites W2130185253 @default.
• W2195280273 cites W2132226366 @default.
• W2195280273 cites W2134226143 @default.
• W2195280273 cites W2134470782 @default.
• W2195280273 cites W2139462186 @default.
• W2195280273 cites W2147275648 @default.
• W2195280273 cites W2148343285 @default.
• W2195280273 cites W2149963540 @default.
• W2195280273 cites W2157703142 @default.
• W2195280273 cites W2166600445 @default.
• W2195280273 cites W2171771055 @default.
• W2195280273 cites W2264976931 @default.
• W2195280273 cites W308661058 @default.
• W2195280273 doi "https://doi.org/10.18632/oncotarget.6536" @default.
• W2195280273 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4792546" @default.
• W2195280273 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26675759" @default.
• W2195280273 hasPublicationYear "2015" @default.
• W2195280273 type Work @default.
• W2195280273 sameAs 2195280273 @default.
• W2195280273 citedByCount "37" @default.
• W2195280273 countsByYear W21952802732016 @default.
• W2195280273 countsByYear W21952802732017 @default.
• W2195280273 countsByYear W21952802732018 @default.
• W2195280273 countsByYear W21952802732019 @default.
• W2195280273 countsByYear W21952802732020 @default.
• W2195280273 countsByYear W21952802732021 @default.
• W2195280273 countsByYear W21952802732022 @default.
• W2195280273 countsByYear W21952802732023 @default.
• W2195280273 crossrefType "journal-article" @default.
• W2195280273 hasAuthorship W2195280273A5010374583 @default.
• W2195280273 hasAuthorship W2195280273A5020647206 @default.
• W2195280273 hasAuthorship W2195280273A5023991993 @default.
• W2195280273 hasAuthorship W2195280273A5030421066 @default.
• W2195280273 hasAuthorship W2195280273A5035783382 @default.
• W2195280273 hasAuthorship W2195280273A5037454723 @default.
• W2195280273 hasAuthorship W2195280273A5041713803 @default.
• W2195280273 hasAuthorship W2195280273A5069411021 @default.
• W2195280273 hasAuthorship W2195280273A5069580321 @default.
• W2195280273 hasAuthorship W2195280273A5086410678 @default.
• W2195280273 hasBestOaLocation W21952802731 @default.
• W2195280273 hasConcept C149532602 @default.
• W2195280273 hasConcept C154317977 @default.
• W2195280273 hasConcept C187316574 @default.
• W2195280273 hasConcept C202751555 @default.
• W2195280273 hasConcept C203014093 @default.
• W2195280273 hasConcept C2777701055 @default.

• next